In my experience things rarely go wrong with a bang there are
usually early indications that things are not as they should be or warning signs that things could go wrong which would trigger an advised transfer in to manage those risks.
Not exact matches
As I've frequently emphasized, the
earliest indications of an oncoming economic shift are
usually observable in the financial markets, particularly in growing deterioration across broad market internals, and widening credit spreads between debt securities of varying creditworthiness.
In practice, it is
usually the first approved
indication that is free of exclusivity protection
earlier in time and generics, while submitting drug applications for an
early market entry, carve out the subsequent
indications from the label to avoid potential infringement of patents which may cover the new approved
indications.